A Brief History of GLP-1 Receptor Agonist Research

Few areas of peptide research have moved as fast, or attracted as much attention, as GLP-1 receptor agonism. What started as an investigation into gut hormones and blood sugar regulation in the 1980s has grown into one of the largest and most active fields in peptide science. Here's the abbreviated version of how it got there.

The incretin effect

The starting point is a phenomenon called the incretin effect, first characterized in the mid-20th century: glucose taken orally triggers a much larger insulin response than the same amount of glucose delivered intravenously. Something released from the gut in response to food was amplifying insulin secretion. Researchers eventually identified two hormones responsible — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), both released from intestinal cells after eating.

GLP-1 turned out to be the more interesting target. In addition to boosting glucose-dependent insulin secretion, it was found to suppress glucagon release, slow gastric emptying, and act on receptors in the brain associated with appetite regulation — a combination that made it an obvious candidate for metabolic research.

The problem: a very short half-life

Native GLP-1 is degraded almost immediately in the body — its circulating half-life is measured in single-digit minutes, broken down rapidly by an enzyme called DPP-4. That made the native hormone essentially useless as a research or therapeutic tool on its own, and set off a decades-long effort to find or engineer a longer-acting alternative.

Exendin-4 and the Gila monster

One of the more unusual chapters in this history involves the Gila monster, a venomous lizard native to the southwestern United States. In the early 1990s, researchers studying its venom identified a peptide called exendin-4, which shares roughly 50% sequence homology with human GLP-1 and activates the same receptor — but critically, resists DPP-4 degradation and has a dramatically longer half-life.

This discovery led directly to exenatide, a synthetic version of exendin-4 and the first GLP-1 receptor agonist to reach approval, in 2005. It validated the entire mechanism and opened the door to a wave of follow-on research.

From daily injections to weekly, and beyond

The years that followed saw a steady push toward longer-acting molecules requiring less frequent dosing, largely achieved through techniques like fatty acid acylation (attaching a lipid chain that promotes albumin binding and slows clearance) and amino acid substitutions that further resist enzymatic breakdown:

• Liraglutide — a fatty-acid-modified GLP-1 analog dosed once daily, approved in 2010.
• Semaglutide — a further-modified analog stable enough for once-weekly dosing, approved in 2017, and one of the most studied GLP-1 compounds in the current literature.
• Tirzepatide — a dual agonist activating both the GLP-1 and GIP receptors, representing a shift toward combining incretin pathways rather than targeting GLP-1 alone.
• Retatrutide — a triple agonist, adding glucagon receptor activity on top of GLP-1 and GIP agonism, currently one of the most active areas of ongoing clinical and preclinical research.

Where the research is heading

Current research interest in this class spans well beyond glucose regulation — investigators are studying downstream metabolic effects, central nervous system signaling, and how multi-receptor agonism changes the pharmacology compared to single-target compounds. The trend line across three decades has been consistent: longer duration of action, broader receptor engagement, and an expanding set of research questions about what these pathways actually do throughout the body.

The GLP-1 story is a useful case study in how a single physiological observation — the incretin effect — can seed decades of downstream peptide engineering once the underlying receptor biology is understood.